Previous Close | 0.0664 |
Open | 0.0674 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0650 - 0.0707 |
52 Week Range | 0.0400 - 0.1195 |
Volume | |
Avg. Volume | 315,356 |
Market Cap | 25.938M |
Beta (5Y Monthly) | 1.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | Oct 17, 2023 - Oct 23, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for RDGL
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRT). The three new clinics are The Myhre Equine Clinic, located in Rochester, New Hampshire, the Hopkinton Animal Hospital, located in Weare, New Hampshire and the Indian Creek Veterinary Hospital, located in Fort Wayne, Indiana. The Myhre Clinic will be focused on providing equine tumor therapy and
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on 1/15/2022. This patent was filed in the USA and internationally via the Patent Cooperation Treaty, PCT. This includes Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia
Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision radionuclide therapy. This includes the shipping containers, the shielded vial holder, the Peltier chiller, and the syringe shields. These device designs are integrated into our production standardization effort. They can be used for treating a range of tumor sizes from 0.5-gram human lymph nodes to half-p